文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

磁共振引导前列腺立体定向体部放疗联合每日在线计划自适应:前瞻性1期试验及补充队列结果

Magnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort.
PubMed 文献 · Adv Radiat Oncol · 2022-03-06

该研究为前列腺癌SMART的1期试验及补充队列,共22例患者接受36.25 Gy/5次照射。急性2级泌尿和胃肠道毒性分别为22.7%和4.5%,无3级以上事件。全部110次分次因解剖改变需计划自适应,再优化后0%计划违反靶区及危及器官指标。

要点

  • 前列腺SMART 36.25 Gy/5次,22例患者中急性2级泌尿毒性22.7%,胃肠道毒性4.5%,无3级以上事件。
  • 全部110次分次均需计划自适应,原因包括危及器官指标超限(68%)或靶区覆盖欠佳(33%)。
  • 再优化前预测计划中靶区、直肠、膀胱、尿道/膀胱颈指标违反率分别为24%、20%、24%、33%,再优化后均为0%。

核心结论

  • 前列腺SMART急性毒性风险低,并改善靶区和危及器官剂量学;每日计划自适应带来的临床获益(包括尿道/膀胱颈保护)需进一步研究。

研究设计与样本

  • 前瞻性1期试验(n=10)加补充队列(n=12),共22例前列腺癌患者,接受SMART 36.25 Gy/5次,主要终点为安全性和可行性。
  • 使用MRIdian直线加速器系统(ViewRay,Inc)实施照射,并评估泌尿和胃肠道毒性及患者报告结局,进行剂量学分析以评估每日计划自适应的获益。

主要发现

  • 中位随访7.9个月,急性2级泌尿和胃肠道毒性分别为22.7%和4.5%,末次随访时分别为4.5%和0%,未观察到3级以上事件。
  • EPIC-26泌尿梗阻评分在SMART期间平均下降9.3分(P=0.03),3个月恢复基线;其他患者报告结局无显著变化。
  • 全部110次分次均需计划自适应,其中68%因危及器官指标超限、33%因解剖改变导致靶区覆盖欠佳。
  • 再优化前预测计划中,最小可接受PTV、直肠、膀胱和尿道/膀胱颈指标违反率分别为24%、20%、24%和33%;再优化后0%计划违反指标。
  • 再优化前剂量学不足的原因包括膀胱充盈变化、精囊位置变化、前列腺体积变化(第3次分次中位增加4.7%,范围0%-56%)以及热点移至尿道/膀胱颈。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 每日计划自适应带来的临床获益(包括尿道/膀胱颈保护)需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic magnetic resonance (MR)-guided adaptive radiation therapy (SMART) for prostate cancer allows for MR-based contouring, real-time MR motion management, and daily plan adaptation. The clinical and dosimetric benefits associated with prostate SMART remain largely unknown. METHODS AND MATERIALS: A phase 1 trial of prostate SMART was conducted with primary endpoints of safety and feasibility. An additional cohort of patients similarly treated with prostate SMART were included in the analysis. SMART was delivered to 36.25 Gy in 5 fractions to the prostate ± seminal vesicles using the MRIdian linear accelerator system (ViewRay, Inc). Rates of urinary and gastrointestinal toxic effects and patient-reported outcome measures were assessed. Dosimetric analyses were conducted to evaluate the specific benefits of daily plan adaptation. RESULTS: The cohort included 22 patients (n = 10 phase 1, n = 12 supplemental) treated in 110 fractions. Median follow-up was 7.9 months. Acute grade 2 urinary and gastrointestinal toxic effects were observed in 22.7% and 4.5%, respectively, and 4.5% and 0%, respectively, at last follow-up. No grade 3+ events were observed. Expanded Prostate Cancer Index-26 urinary obstructive scores decreased during SMART (mean, 9.3 points; P = .03) and returned to baseline by 3 months. No other significant changes in patient-reported outcome measures were observed. One-hundred percent of fractions required plan adaptation owing to exceeding organ-at-risk metrics (68%) or suboptimal target coverage (33%) resulting from anatomic changes. Minimum acceptable planning target volume, rectal, bladder, and urethra/bladder neck metrics were violated in 24%, 20%, 24%, and 33% of predicted plans, respectively; 0% of reoptimized plans violated metrics. Underlying causes for deficient dosimetry before reoptimization included changes in bladder filling, seminal vesicle position, prostate volume (median 4.7% increase by fraction 3; range, 0%-56%), and hotspots shifting into urethra/bladder neck. CONCLUSIONS: Prostate SMART results in low risk of acute toxic effects with improvements in target and organ-at-risk dosimetry. The clinical benefits resulting from daily plan adaptation, including urethra/bladder neck protection, warrant further investigation.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Leeman JE, Cagney DN, Mak RH, et al. Magnetic Resonance-Guided Prostate Stereotactic Body Radiation Therapy With Daily Online Plan Adaptation: Results of a Prospective Phase 1 Trial and Supplemental Cohort. Adv Radiat Oncol. 2022. PMID: 35847547. doi:10.1016/j.adro.2022.100934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。